Side-by-side · Research reference

GlutathionevsMelanotan-II

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED6/39 cited

BPhase 1HUMAN-REVIEWED9/43 cited

Glutathione

Endogenous Tripeptide · Antioxidant

γ-Glu-Cys-GlyStructure

UbiquitousTissue distribution

GCL + GSBiosynthesisWang 2026 Aiana 2026

IV · Oral · Inhaled

Melanotan-II

MC1R + MC4R agonist · Tanning + sexual response

0.25–1.0 mgPer doseDorr 1996

Phase 1Evidence levelDorr 1996

~1 hrHalf-life

SQ · Abdomen · Loading 5–7 days, then maintenance

01Mechanism of Action

Parameter

Glutathione

Melanotan-II

Primary target

Intracellular redox systems, glutathione peroxidase, glutathione transferase

MC1R (skin) + MC3R + MC4R (CNS sexual / appetite)Dorr 1996

Pathway

Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH

MC1R agonism → melanocyte tyrosinase → eumelanin synthesis. MC4R → autonomic sexual arousal centresDorr 1996 Simerly 2023

Downstream effect

Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction

Skin darkening, photo-protection, increased sexual desire / spontaneous erectionDorr 1996

Feedback intact?

—

Origin

Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025 Hecht 2026

Cyclic 7-AA modified α-MSH analog; designed at University of ArizonaDorr 1996

Antibody development

—

02Dosage Protocols

Parameter

Glutathione

Melanotan-II

Endogenous synthesis

Hepatic synthesis ~10 g/day (basal rate)

Tissue-specific; demand-driven upregulation via Nrf2 signaling.

—

Exogenous oral

250–1000 mg/day

Bioavailability limited; gastric hydrolysis reduces systemic uptake.

—

IV supplementation

600–1200 mg (research protocols)

Used in clinical oxidative stress and hepatic detoxification studies.

—

Precursor strategy

N-acetylcysteine (NAC) 600–1200 mg/day

Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.

—

Evidence basis

Animal mechanistic + human mechanistic

Phase 1 + anecdotalDorr 1996

Loading phase

—

0.25–0.5 mg/day SQ × 5–7 daysDorr 1996

Builds up to visible tan.

Maintenance

—

0.5–1.0 mg 1–2×/week

After visible tan develops; supports with UV exposure.

Frequency

—

Daily during loading; 1–2× per week maintenance

Lower / starter dose

—

0.1 mg / day

Conservative starter — assess tolerability for nausea.

Duration

—

8–12 weeks per cycle

Reconstitution

—

Bacteriostatic water; protect from light

Timing

—

Evening preferred (24h tan-development cycle)

Half-life

—

~1 hour plasma; effects on melanocytes persist days

04Side Effects & Safety

Parameter

Glutathione

Melanotan-II

Oral supplementation

GI discomfort, bloating (mild, dose-dependent)

—

IV administration

Rare hypersensitivity, infusion site reaction

—

Inhalation

Bronchospasm risk in asthma (rare)

—

Tumor metabolism

Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026

—

Nausea

—

Common, especially loading phase

Flushing

—

Common transient

Spontaneous erection

—

Common in men — MC4R cross-effectDorr 1996

Increased mole / freckle pigmentation

—

Existing moles darken; new lesions possible

Melanoma risk

—

Theoretical concern — increased melanocyte activity; CAUTION in melanoma history

Appetite suppression

—

MC4R-mediated; mild

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

Glutathione

—

Melanotan-II

·History of melanoma or atypical mole syndrome
·Pregnancy / breastfeeding
·Active uncontrolled hypertension

Relative Contraindications

Glutathione

·Active malignancy (theoretical cysteine supply risk)Hecht 2026
·Severe asthma (inhaled formulations)

Melanotan-II

·Significant freckling / dysplastic nevus
·Personal or family melanoma history

05Administration Protocol

Parameter

Glutathione

Melanotan-II

1. Oral administration

Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.

Add 2 mL bacteriostatic water to 10 mg vial → 5 mg/mL = 500 mcg per 0.1 mL. Light-protected.

2. Intravenous

Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.

SQ — abdomen. Rotate sites.

3. Inhaled formulations

Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.

Evening preferred. UV exposure (sunlight or tanning bed) helps develop tan.

4. Precursor supplementation

N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G insulin syringe.